Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Rallybio

Rallybio

Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry leaders.

Making science’s hardest obstacles our highest priority.

Frustrated by the fact that so many devastating diseases still lack adequate treatments, we’ve made it our mission to discover, develop, manufacture, and deliver therapies that meaningfully improve the lives of patients.

Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward no one has attempted before. And of course, it means striving to develop and deliver the truly transformational.

Following the science wherever it goes.

Developing and delivering transformative therapies starts with access to high-quality product candidates. The trick is finding them. At Rallybio, we believe we have two unique advantages. First, our decades of experience in drug discovery, research, development, regulatory strategy, and manufacturing help us more effectively source, identify, and evaluate therapeutic targets and product candidates with a high probability of success. At the same time, we have an extensive network of relationships with leaders in industry and in academic clinical centers worldwide who know just what we’re looking for—and what we are capable of achieving.

Timeline

July 29, 2021
Rallybio raises a $81,000,000 initial public offering from 5AM Ventures, Canaan Partners, Fairview Capital Partners, Global Investment Partners, Mitsui Global Investment, New Leaf Venture Partners, Pivotal bioVenture Partners, Solasta Ventures and The Rise Fund.
May 18, 2020
Rallybio secures $145M and unveils lead rare disease programy.
April 25, 2018
Rallybio raises a $37,000,000 series A round.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
July 29, 2021
FierceBiotech
After filing to raise up to $100 million in its Wall Street debut, Rallybio is reeling in a smaller sum of $80.6 million. The funds will bankroll several clinical trials, including a phase 1/2 study of its lead asset in a rare fetal bleeding disorder.
Kate Goodwin
July 6, 2021
BioSpace
Tossing their names in the hat just before long weekend, four life sciences companies filed for $100 million IPOs Friday afternoon.
Amirah Al Idrus
July 6, 2021
FierceBiotech
Rallybio ended the first quarter with nearly $128 million in the bank, and it's heading to Wall Street for more. The company filed Friday to raise up to $100 million in its IPO, which will advance a pair of treatments for a rare fetal bleeding disorder through phase 1 as well as get programs for complement disorders into the clinic.
Annalee Armstrong
July 2, 2021
FierceBiotech
2018 Fierce15 winner Rallybio has established proof-of-concept for an antibody treatment aiming to prevent a rare disease that causes a mother's immune system to attack her fetus or newborn child's platelets. Rallybio is conducting a phase 1/2 study of RLYB211 to prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), which can cause uncontrollable bleeding in fetuses and newborns.
Nick Paul
January 21, 2021
FierceBiotech
Rallybio has hired Steven Tuch to lead corporate development. Tuch arrives at Rallybio on the back of almost nine years at BMO Capital Markets that saw him rise to the position of head of U.S. equity capital markets originations.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.